Cargando…
Development of [(124/125)I]IAZA as a New Proteinopathy Imaging Agent for Alzheimer’s Disease
Radioiodinated imaging agents for Aβ amyloid plaque imaging in Alzheimer’s disease (AD) patients have not been actively pursued. Our previous studies employed the “diaza” derivatives [(11)C]TAZA and [(18)F]flotaza in order to develop successful positron emission tomography (PET) imaging agents for A...
Autores principales: | Reddy, Thrisha T., Iguban, Michael H., Melkonyan, Lusine L., Shergill, Jasmine, Liang, Christopher, Mukherjee, Jogeshwar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863004/ https://www.ncbi.nlm.nih.gov/pubmed/36677925 http://dx.doi.org/10.3390/molecules28020865 |
Ejemplares similares
-
[(124)I]IBETA: A New Aβ Plaque Positron Emission Tomography Imaging Agent for Alzheimer’s Disease
por: Nguyen, Grace A.H., et al.
Publicado: (2022) -
[(125)I]INFT: Synthesis and Evaluation of a New Imaging Agent for Tau Protein in Post-Mortem Human Alzheimer’s Disease Brain
por: Limpengco, Roz R., et al.
Publicado: (2023) -
Radiation Dosimetry of Theragnostic Pairs for Isotopes of Iodine in IAZA
por: Jans, Hans-S., et al.
Publicado: (2022) -
Pharmacokinetics and Scintigraphic Imaging of the Hypoxia-Imaging Agent [(123)I]IAZA in Healthy Adults Following Exercise-Based Cardiac Stress †
por: Stypinski, Daria, et al.
Publicado: (2018) -
Measurement of Aβ Amyloid Plaques and Tau Protein in Postmortem Human Alzheimer’s Disease Brain by Autoradiography Using [(18)F]Flotaza, [(125)I]IBETA, [(124/125)I]IPPI and Immunohistochemistry Analysis Using QuPath
por: Mondal, Rommani, et al.
Publicado: (2023)